Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 22, 2026, a projected date rather than a confirmed one. There are 5 upcoming events on record.
Cash runway is approximately 26.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 9 concluded trials, 78% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 22, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| December 15, 2026 | A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety | Trial Milestone | Phase 3 |
| December 15, 2026 | A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine | Trial Milestone | Phase 3 |
| January 15, 2027 | Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures | Trial Milestone | Phase 3 |
| May 31, 2028 | Clinical Trial of Vormatrigine in Adult Patients With Epilepsy | Trial Milestone | Phase 3 |
Track PRAX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open PRAX in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.